Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Aprovel, Fensoberax, Ifirmasta, Irbesartan, Irbetyrol, Karvea; Belgium: Aprovel; Bulgaria: Aprovel, Irbesartan, Karvea; Cyprus: Karvea; Czech Republic: Aprovel, Ifirmasta, Irbesartan, Karvea; Denmark: Aprovel, Karvea; Estonia: Aprovel, Irbesartan, Iprestan, Karvea; France: Aprovel; Germany: Aprovel, Ifirmasta, Irbesartan, Karvea, Mefam; Greece: Aprovel, Irbesartan, Karvea; Hungary: Aprovel, Irbec, Irbesartan, Irprestan, Irtucalan, Karvea; Ireland: Aprovel, Ifirmasta, Irbesan, Irbesartan, Irprestan, Karvea; Italy: Aprovel, Karvea; Latvia: Aprovel, Ifirmasta, Irbesartan, Karvea; Lithuania: Aprovel, Ifirmasta, Irbesartan, Karvea; Luxembourg: Aprovel, Irbesartan, Karvea; Malta: Aprovel, Ifirmasta, Irbesartan, Karvea; Netherlands: Aprovel, Artivesan, Irberan, Irbesartan, Irtec, Karvea; Poland: Aprovel, Ifirmasta, Irbesartan, Karvea; Portugal: Abavil, Aprovel, Ifirmasta, Irbesartan, Karvea; Romania: Aprovel, Irbec, Irbegamma, Irbesartan, Irkartaban, Karvea; Slovakia: Aprovel, Ifirmasta, Irbesartan, Irtucalan, Karvea; Slovenia: Aprovel, Iraben, Irbesartan, Karvea; Spain: Aprovel, Irbesartan, Karvea; Sweden: Aprovel, Ifirmasta, Irbesartan, Karvea; UK: Aprovel.

North America

Canada: Avapro; USA: Avapro.

Latin America

Argentina: Adana, Aprovel, Avapro; Brazil: Aprovel, Ávapro; Mexico: Aprovel, Avapro.


Japan: Avapro, Irbetan.

Drug combinations

Irbesartan and Hydrochlorothiazide


Irbesartan: C~25~H~28~N~6~O. Mw: 428.53. (1) 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-; (2) 2-Butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one. CAS-138402-11-6 (1996).

Pharmacologic Category

Angiotensin II Receptor Antagonists. (ATC-Code: C09CA04).

Mechanism of action

Irbesartan binds to AT1 angiotensin II receptor. This binding prevents angiotensin II from binding to receptor, thereby blocking the vasoconstriction and aldosterone-secreting effects of angiotensin II.

Therapeutic use

Treatment of hypertension alone or in combination with other antihypertensives. Treatment of diabetic nephropathy in type 2 diabetes mellitus (non-insulin-dependent, NIDDM) and hypertension.

Pregnancy and lactiation implications

Possible fetal harm and/or death if used in 2^nd^ and 3^rd^ trimesters of pregnancy. Angiotensin II receptor antagonists should be avoided in the first three months of pregnancy. Contraindicated during lactation.

Unlabeled use

To slow rate of progression of aortic-root dilation in pediatric patients with Marfan’s syndrome.


Hypersensitivity to irbesartan or any component of the formulation.

Warnings and precautions

Hyperkalemia might occur. Renal function deterioration and/or increases in serum creatinine. Use with caution in significant aortic/mitral stenosis, in unstented unilateral/bilateral renal artery stenosis, or with pre-existing renal insufficiency, and severe renal impairment. May cause injury and death to developing fetus when used in 2^nd^ and 3^rd^ trimesters of pregnancy. Possible symptomatic hypotension, particularly in volume- and/or salt-depleted patients. Anaphylactoid reactions and/or angioedema possible. Possible oliguria, progressive azotemia, and, rarely, acute renal failure and/or death in severe CHF. Blood pressure reduction may be smaller in black patients.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart